Ramesh Kumar - Onconova Therapeutics Co-Founder, CEO and President and Director
| ONTXDelisted Stock | USD 7.93 0.00 0.00% |
CEO
Dr. Ramesh Kumar, Ph.D., is Chief Executive Officer, Director of Onconova Therapeutics, Inc. Prior to founding the company, Dr. Kumar held positions in research and development or management at Princeton University, BristolMyers Squibb Company, or BristolMyers Squibb, DNX Corporationration and Kimeragen, Inc., a genomics company, where he was President of the Genomics and Transgenics Division since 2018.
| Age | 58 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | 267 759 3680 |
| Web | https://www.onconova.com |
Onconova Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3807) % which means that it has lost $0.3807 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.843) %, meaning that it created substantial loss on money invested by shareholders. Onconova Therapeutics' management efficiency ratios could be used to measure how well Onconova Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | CEO Age | ||
| Steven Lo | Vaxart Inc | 57 | |
| Lisa Conte | Jaguar Animal Health | 65 | |
| Robert Clarke | Pulmatrix | 46 | |
| William Stilley | Adial Pharmaceuticals | 49 | |
| Robert McNally | GeoVax Labs | 69 | |
| Michael Ward | Aeterna Zentaris | 58 | |
| Cary MBA | Adial Pharmaceuticals | 63 | |
| Klaus Paulini | Aeterna Zentaris | N/A | |
| Teofilo MBA | Pulmatrix | 54 | |
| Teofilo Raad | Pulmatrix | 48 | |
| Jeffery FCMA | VBI Vaccines | 63 | |
| Jeff Baxter | VBI Vaccines | 52 | |
| Wouter Latour | Vaxart Inc | 60 | |
| Curtis Lockshin | VBI Vaccines | 55 | |
| Joseph Patti | Vaxart Inc | 51 | |
| J Finley | Palisade Bio | 66 | |
| Shankar MBA | Ocugen Inc | 60 | |
| Ted Raad | Pulmatrix | 48 | |
Management Performance
| Return On Equity | -0.84 | |||
| Return On Asset | -0.38 |
Onconova Therapeutics Leadership Team
Elected by the shareholders, the Onconova Therapeutics' board of directors comprises two types of representatives: Onconova Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Onconova. The board's role is to monitor Onconova Therapeutics' management team and ensure that shareholders' interests are well served. Onconova Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Onconova Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henry Bienen, Director | ||
| Ramesh Kumar, Co-Founder, CEO and President and Director | ||
| Anne VanLent, Director | ||
| Ajay Bansal, CFO and Secretary | ||
| Premkumar Reddy, Founder, Lead Scientific Advisor and Director | ||
| Jerome Groopman, Director | ||
| James Marino, Independent Director | ||
| Manoj Maniar, Sr. VP of Product Devel. | ||
| Thomas McKearn, President - Research and Development | ||
| Abraham Oler, Vice President Corporate Development and General Counsel | ||
| Michael Hoffman, Chairman of the Board | ||
| Jack Stover, Director | ||
| Mark CPA, CFO COO | ||
| Victor MD, Chief Officer | ||
| Steven Fruchtman, Senior Vice President - Research and Development, Chief Medical Officer | ||
| Mark Guerin, Principal Accounting Officer and VP of Financial Planning and Accounting | ||
| Steven MD, President CEO | ||
| Mark MD, Chief Officer | ||
| Viren Mehta, Director | ||
| Adar Silverstein, Sr Devel |
Onconova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Onconova Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.84 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (89.28) % | |||
| Current Valuation | (4.56 M) | |||
| Shares Outstanding | 21 M | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 7.95 % | |||
| Number Of Shares Shorted | 20.7 K | |||
| Price To Earning | (0.87) X | |||
| Price To Book | 1.43 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Onconova Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Onconova Therapeutics' short interest history, or implied volatility extrapolated from Onconova Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Onconova Stock
If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |